A direct comparative study of 5 vaccines in Hungary shows Russian Sputnik V vaccine has the highest 98% efficacy in preventing the virus-related mortality
NEW DELHI/ MOSCOW, Nov 25 (The CONNECT) – A unique independent nationwide observational study in EU member state Hungary estimating and directly comparing efficacy of five vaccines against COVID has demonstrated that the Russian Sputnik V vaccine has the highest 98% efficacy in preventing the virus-related mortality and 85.7% efficacy against coronavirus infection leading alongside the vaccine by Moderna.
The study based on the real world data from 3.7 million vaccinated individuals in Hungary is available here
Hungary was the first country in EU to authorize Sputnik V. The article analyses data from the National Public Health Center (NPHC).
Between 22 January 2021 and 10 June 2021, residents of Hungary received two doses of Sputnik V, Moderna, Pfizer-BioNTech, Sinopharm or AstraZeneca vaccines as part of the national vaccination program. The Russian vaccine proved the best in protection against COVID related mortality and leads alongside the vaccine by Moderna in efficacy rate against COVID infection based on analysis of data from 820,000 individuals vaccinated with Sputnik V (see the chart below). The study has also demonstrated Sputnik V is 100% effective against COVID related deaths in individuals aged 16–44 years.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF), said: “With 98% efficacy in preventing COVID-related mortality and 85.7% efficacy against coronavirus infection Sputnik V has demonstrated the best results among five vaccines (Sputnik V, Moderna, Pfizer-BioNTech, Sinopharm and AstraZeneca) administered in EU member state Hungary as part of an independent study based on data from 3.7 million people.”
RDIF is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling RUB 2.1tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than one million people and generate revenues which equate to more than 6% of Russia’s GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 bn.